Needham analyst Rajvindra Gill upgraded Nvidia to Buy from Hold with a $270 price target. During these uncertain times, investors will “flock to companies with superior balance sheets and robust free cash flow,” Gill tells investors in a research note. Nvidia fits the bill, says the analyst. Further, Gill believes GPUs for medical applications will ramp in light of the COVID-19 pandemic. And with Nvidia shares down ~35% from their peak, the stock trades at a multi-year price-to-earnings valuation low, contends the analyst.